Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SARomics Biostructures and Red Glead Discovery Enters into Drug Discovery Collaboration

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
The companies will perform a joint collaborative project with the goal of developing novel lead compounds against epigenetic pathway targets.

SARomics Biostructures and Red Glead Discovery have announced that they have entered into a drug discovery collaboration.

Targeting proteins involved in epigenetic mechanisms (the cellular processes associated with the modification of chromatin) have emerged as an important new therapeutic opportunity for treating cancer, diabetes, inflammatory diseases and more.

By merging the unique and highly complementary capabilities of the two companies, an efficient and versatile fragment-based lead discovery (FBLD) platform is enabled.

The advanced structural biology platform and expertise contributed by SARomics Biostructures are combined with the bioassay technology and medicinal chemistry skills of Red Glead Discovery.

The scientific excellence of the alliance is reflected by the track record of Red Glead Discovery for delivery of lead compounds and the established platform for structure-based drug design implemented by SARomics Biostructures.

For the project, the companies will share costs and the generated intellectual property rights.

Project progress and the discovery of lead compounds will be effectuated by utilization of FBLD, which is a powerful alternative to costly and resource-intensive high-throughput screening (HTS) campaigns.

At this stage of the project, the collaboration will be run without external financing.

Björn Walse, CEO of SARomics Biostructures, said “We are excited about the opportunity to work with Red Glead Discovery on this frontline project that clearly leverages the competitiveness of both companies. We see this initiative as highly complementary to SARomics’ other collaborations, such as those within KINOMED, which focus on protein kinase off-the-shelf crystal structures and fragment complexes.”

Johan Evenäs, CEO of Red Glead Discovery, added “I am convinced that we have a perfect match of competences and experiences enabling a project that would have been difficult for either company alone at this stage. We expect the close proximity of our two companies within the Lund Life Science Incubator at Medicon Village to further facilitate effective collaboration.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SARomics Biostructures and Xbrane Bioscience Form a Strategic Partnership
Strategic partnership to deliver “off-the-shelf” protein structure services.
Thursday, January 30, 2014
A New EU-Funded Industry-Academia Drug Discovery Partnership Targets Challenging Kinases
Industry and academia join to create the Translational Kinase Tumor Inhibitor Discovery Consortium.
Wednesday, April 10, 2013
SARomics Biostructures Brings in New Strategic Owners
Innovationsbron AB and LUIS AB are investing in and becoming new co-owners of the company.
Saturday, September 15, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!